Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Pfizer and BioNTech share data with FDA on COVID-19 vaccines for younger children as Sanofi pivot on its mRNA COVID-19 vaccine, shifting focus toward other infectious diseases instead.
Avanir is developing its future leadership from within through a program it calls “Leading at Avanir,” which focuses on emotional intelligence and situational leadership components.
Peter Marks will serve as acting director of the Office of Vaccines Research and Review at the U.S. FDA following the resignation of two top officials at the agency.
Less than a month after appointing a new chief executive officer, Ziopharm Oncology announced a restructure that has resulted in over 50% of its workforce being axed.
Here’s a look at a few of the industry expansions that have been announced so far this month.
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
Eriksson said that HMNC Brain Health is a pioneer in developing precision medicine for the psychiatric space.
Industry watchers question why Elizabeth Holmes has been singled out for failing to deliver what she promised while other tech executives are given a pass.
Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.
Diabetes player Novo Nordisk cut a deal this week, announcing a settlement agreement to put an end to a lawsuit filed in January 2017 by American Depository Receipt investors.
Biohaven Pharma’s latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy showed that it did not meet its expected outcomes.
The company aims to treat different forms of mental illness and brain disorders with its pipeline.